Delivering Novel Anti-Viral Therapies

to Patients with Weakened Immune Systems

ABOUT

AiCuris is meeting the needs of the growing population of immunocompromised people who require precise therapies to effectively treat infection. Our flagship product, PREVYMIS®, marketed by our partner MSD, prevents CMV in a defined group of transplant recipients. Our pivotal Phase 3 candidate pritelivir aims to address recurrent and resistant HSV infections in a broad population of patients with weakened immune systems. For immunocompromised people, an otherwise manageable infection can mean life or death. AiCuris, with its expertise and growing pipeline, is committed to providing therapeutic solutions for them now and in the future.

Latest News

2024-10-31

AiCuris Initiates First-in-Human Phase 1 Trial with Antiviral Agent AIC468 to Address BK Virus Infections in Kidney Transplant Recipients

AiCuris has initiated its Phase 1 trial to evaluate the safety, tolerability and pharmacokinetics of AIC468, an antiviral ASO, in healthy volunteers.

Read more

2024-07-30

AiCuris Appoints Cynthia Wat as Chief Medical Officer

AiCuris has appointed Dr. Cynthia Wat, a highly accomplished pharmaceutical physician with over 25 years of experience, as Chief Medical Officer. Dr. Wat will lead the management and global development of AiCuris' clinical pipeline of innovative therapeutic candidates.

Read more

2024-07-17

AiCuris Announces Milestone Achievements Further Validating its Pipeline of Anti-viral Solutions for Immuno-compromised Patients

AiCuris reached major milestones in 1H 2024 for letermovir (marketed by MSD as PREVYMIS®), pritelivir, and AIC468 highlighting the rapid progress in developing anti-viral solutions for immunocompromised patients.

Read more